Stifel raises target for STAAR Surgical stock from USD 28 to USD 31
Published on 10/15/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Stifel raised its target from USD 28.00 to USD 31.00 on September 29, 2026.
- Second-quarter 2026 revenue reached USD 93.53 million, up 111.1 percent year over year.
- STAAR Surgical stock trades at EUR 19.50 at 12:28 p.m. CEST at Lang & Schwarz on October 15, 2026.
STAAR Surgical (ISIN US8523123052) saw Stifel raise its price target from USD 28.00 to USD 31.00 on September 29, 2026, according to The Globe and Mail. The analyst cited stronger international sales momentum and a potential recovery in China.
Recent events reset the narrative
STAAR Surgical also appointed Andrew Pilon as vice president of business development on October 8, 2026, according to the STAAR Surgical investor site. The company develops implantable phakic intraocular lenses and sells its products in more than 85 countries.
Its board approved a USD 50.00 million share repurchase authorization on September 24, 2026. The authorization covered up to 5.2 percent of outstanding shares, according to MarketBeat.
What did the second quarter show?
STAAR Surgical reported USD 93.53 million in second-quarter 2026 revenue, up 111.1 percent from USD 44.32 million in the second quarter of 2025. Net income reached USD 8.06 million, compared with a USD 14.80 million loss in the year-earlier quarter, while diluted earnings per share were USD 0.16, according to Simply Wall St. The quarter therefore combined triple-digit revenue growth with a return to profitability.
Dates for the next update
MarketBeat estimates that STAAR Surgical will report third-quarter 2026 results on November 4, 2026, after the market closes.
Stock price and investor context
STAAR Surgical stock was trading at EUR 19.50 at Lang & Schwarz on October 15, 2026 at 12:28 p.m. CEST. The primary Nasdaq listing closed at USD 21.84 on October 14, 2026, while its market capitalization was USD 1.1 billion and its 52-week range was USD 15.59 to USD 35.87.
The combination of a higher analyst target, a buyback and a new commercial executive gives the stock several company-specific reference points. The operating test remains whether second-quarter growth and the return to profit can continue through the planned third-quarter update.
The further course of trading is shown by the continuously updated real-time quote of STAAR Surgical stock.
STAAR Surgical stock at a glance
- Company: STAAR Surgical Company
- ISIN: US8523123052
- Ticker: STAA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 12:28 p.m. CEST): EUR 19.50
- Market capitalization: USD 1.1 billion (as of October 14, 2026)
- 52-week range: USD 15.59-35.87 (as of October 14, 2026)
- Sector / Industry: Health care / medical instruments and supplies
Market context: Market report S&P 500.
